NAUT NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: .

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .

Media Contact

Investor Contact



EN
11/04/2024

Underlying

NAUTNAUTILUS BIOTECHNOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NAUTILUS BIOTECHNOLOGY INC

 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Reports First Quarter 2024 Financial Results

Nautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. “We continued to make solid progress against our core development goals in Q1,” said Sujal Patel, CEO of Nautilus.   “We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software and continue to see mea...

April 30, 2024 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Announce First Quarter 2024 Financial Result...

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024 SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the we...

April 11, 2024 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Fin...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform”, said Sujal Patel,...

February 28, 2024 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Heal...

Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 44th Annual Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Wednesday, March 6th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “I...

February 22, 2024 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 F...

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business develop...

February 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch